Page 16 - John Redd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Why a drug therapy that could ease record Covid hospitalizations has gone largely unused Erika Edwards © Provided by NBC News A drug that could protect high-risk Covid-19 patients from developing severe illness is sitting on shelves unused as a record number of people are hospitalized in the U.S. On Thursday, public health officials at the federal and state levels pleaded with the country to take advantage of its vast supply of monoclonal antibody treatments, the only available therapy that can potentially keep patients out of the hospital. "This is the first time during the...

Demand is low for COVID-19 antibody drugs but shortages loom FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. (Courtesy of Eli Lilly via AP) Published December 19. 2020 12:15AM  By MARILYNN MARCHIONE, AP Chief Medical Writer U.S. healt...

Demand is low for COVID-19 antibody drugs but shortages loom Marilynn Marchione Updated:  Tags:  FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. (Courtesy of Eli Lilly via AP) (Eli Lilly) U.S. health officials are seeing an astonishi...

10:15 EDT, 18 December 2020 U.S. health officials are seeing an astonishing lack of demand for COVID-19 medicines that may help keep infected people out of the hospital, drugs they rushed out to states over the past few weeks as deaths set new records. Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from these drugs, which supply antibodies to help the immune system fight the coronavirus. Only 5% to 20% of doses the federal government allocated have been used. Ironically, government advisers met Wednesday and Thursday to plan for the opp...

Marilynn Marchione FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. (Courtesy of Eli Lilly via AP) December 18, 2020 - 6:02 AM U.S. health officials are seeing an astonishing lack of demand for COVID-19 medic...